中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2012年
1期
54-57
,共4页
常毅娜%鞠现霞%崔琴%王坤林%周红文
常毅娜%鞠現霞%崔琴%王坤林%週紅文
상의나%국현하%최금%왕곤림%주홍문
Fabry病%α-半乳糖苷酶A%外周血粒细胞%血浆%筛查
Fabry病%α-半乳糖苷酶A%外週血粒細胞%血漿%篩查
Fabry병%α-반유당감매A%외주혈립세포%혈장%사사
Fabry disease%α-Galactosidase A%Peripheral blood granulocytes%Plasma%Screening
测定100名体检者与1例Fabry病患者的外周血粒细胞和血浆中的d-半乳糖苷酶A(α-GalA)活性.结果显示,100名受试者外周血粒细胞与血浆中的α-GalA活性平均值分别为(51.97±15.24)nmol·h-1·mg-1和(148.08±26.30) nmol·h-1·ml-1;其血浆中α-Gal A活性与外周血粒细胞α-Gal A活性呈正相关(r=0.533,P<0.01);Fabry病患者外周血粒细胞与血浆中α-Gal A活性分别为1.05 nmol· h-1·mg-1和10.06 nmol·h-1·ml-1,均明显低于所测定人群酶活性范围下限.提示血浆与外周血粒细胞α-GalA活性均可用于Fabry病的筛查和诊断.
測定100名體檢者與1例Fabry病患者的外週血粒細胞和血漿中的d-半乳糖苷酶A(α-GalA)活性.結果顯示,100名受試者外週血粒細胞與血漿中的α-GalA活性平均值分彆為(51.97±15.24)nmol·h-1·mg-1和(148.08±26.30) nmol·h-1·ml-1;其血漿中α-Gal A活性與外週血粒細胞α-Gal A活性呈正相關(r=0.533,P<0.01);Fabry病患者外週血粒細胞與血漿中α-Gal A活性分彆為1.05 nmol· h-1·mg-1和10.06 nmol·h-1·ml-1,均明顯低于所測定人群酶活性範圍下限.提示血漿與外週血粒細胞α-GalA活性均可用于Fabry病的篩查和診斷.
측정100명체검자여1례Fabry병환자적외주혈립세포화혈장중적d-반유당감매A(α-GalA)활성.결과현시,100명수시자외주혈립세포여혈장중적α-GalA활성평균치분별위(51.97±15.24)nmol·h-1·mg-1화(148.08±26.30) nmol·h-1·ml-1;기혈장중α-Gal A활성여외주혈립세포α-Gal A활성정정상관(r=0.533,P<0.01);Fabry병환자외주혈립세포여혈장중α-Gal A활성분별위1.05 nmol· h-1·mg-1화10.06 nmol·h-1·ml-1,균명현저우소측정인군매활성범위하한.제시혈장여외주혈립세포α-GalA활성균가용우Fabry병적사사화진단.
α-Galactosidase A (α-Gal A ) activities in plasma and peripheral blood granulocytes of 100healthy subjects and one patient with Fabry disease was determined by means of fluorogenic substrate.The results showed that the enzymatic activities of peripheral blood granulocytes and plasma in 100 subjects were (51.97 ± 15.24)and(148.08±26.30) nmol · h-1 · ml-1 respectively.The α-Gal A activities in plasma and granulocytes were positively correlated( r=0.533,P<0.01 ).The enzymatic activities in peripheral blood granulocytes and plasma of the patients with Fabry disease were 1.05 and 10.06 nmol · h-1 · ml-1 respectively,both much lower than those of 100healthy subjects.These results suggest that α-Gal A activity in plasma and peripheral blood granulocytes can be used for diagnosis and screening of Fabry disease.